Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Apellis Pharmaceuticals (NASDAQ:APLS) posted its quarterly earnings results on Friday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08, Zacks reports. The firm had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.73) EPS.

Apellis Pharmaceuticals Stock Down 3.3 %

Shares of APLS opened at $25.15 on Friday. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of -12.39 and a beta of 0.96. Apellis Pharmaceuticals has a 1 year low of $24.33 and a 1 year high of $66.00. The business’s 50 day simple moving average is $30.04 and its 200-day simple moving average is $31.62. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Insider Transactions at Apellis Pharmaceuticals

In related news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the sale, the insider now owns 55,560 shares in the company, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the sale, the chief accounting officer now owns 48,138 shares in the company, valued at $1,464,839.34. The trade was a 2.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,365 shares of company stock valued at $1,810,479 in the last ninety days. Corporate insiders own 6.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Scotiabank lowered their price target on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Thursday, February 13th. Robert W. Baird decreased their target price on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC decreased their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).